Skip to main content
  • Saved

made a Post

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study

Source : https://doi.org/10.1080/2162402X.2019.1682383

We conducted a retrospective cohort study in all consecutive patients treated with nivolumab or pembrolizumab off clinical trials at the Toulouse University Cancer Institute ( Institut Universitaire du Cancer de Toulouse {IUCT}, France), a tertiary referral center for cancer.

Sign In or Register Today to Access This Content